The race to commercialize cell and gene therapies (CGT) is heating up. Almost all of top 20 pharma have dedicated strategies, while US policy makers and the FDA are facilitating innovation and accelerating pathways to market.
With so few treatments on the market to benchmark against in terms of commercial strategy, and a relatively unknown understanding of the long-term patient journey, the industry knows it has huge challenges to overcome.
It's not good enough to sell patients and physicians on the dream. We must forge the way alongside government and payers to build new reimbursement models, and scale manufacturing with the optimal patient journey at the centre. All of this while continuing to identify new patient populations to ensure long-term commercial success.
Cell and Gene Therapy USA by Reuters Events will bring together over 2000 key stakeholders to drive new collaboration, define commercialization approaches and get solutions to patients faster.
General Admission: USD 0.00
Time: 09:30 to 16:30